Theriva Biologics Balance Sheet Health
Financial Health criteria checks 3/6
Theriva Biologics has a total shareholder equity of $24.6M and total debt of $163.0K, which brings its debt-to-equity ratio to 0.7%. Its total assets and total liabilities are $40.1M and $15.5M respectively.
Key information
0.7%
Debt to equity ratio
US$163.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$16.41m |
| Equity | US$24.64m |
| Total liabilities | US$15.47m |
| Total assets | US$40.11m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: TOVX's short term assets ($19.5M) exceed its short term liabilities ($7.3M).
Long Term Liabilities: TOVX's short term assets ($19.5M) exceed its long term liabilities ($8.2M).
Debt to Equity History and Analysis
Debt Level: TOVX has more cash than its total debt.
Reducing Debt: TOVX's debt to equity ratio has increased from 0% to 0.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TOVX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TOVX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 5.4% each year